San Francisco, CA, United States of America

Frederic Waldman

This inventor holds 20 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Colorectal Cancer Research. Top assignees: University of California, Quest Diagnostics Investments, Inc., Clinical Genomics Pty. Ltd.. Active years: 1997-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frederic Waldman. Retrieved from https://idiyas.com/inventor/frederic-waldman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 6)

% Patents Active = 80.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 5.1

ph-index = 8

Forward Citations = 526(Granted Patents)

Location History:

San Francisco, CA (US) (1997 - 2011)
San Juan Capistrano, CA (US) (2018 - 2024)

Company Filing History:

12 out of 16,048

University of California

patents

8 out of 499

Quest Diagnostics Investments, Inc.

patents

2 out of 10

Clinical Genomics Pty. Ltd.

patents

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

Areas of Expertise:

Methylated Markers

Colorectal Cancer

Next-Gen Sequencing

Solid Tumors

Mutations

Genomic Hybridization

Breast Cancer

Nucleic Acid Detection

Comparative Genomics

Tumor Screening

Chromosomal Abnormalities

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12467098 - METHYLATED MARKERS FOR COLORECTAL CANCER (2025-11-11),

2. 12264357 - Universal Sanger sequencing from next-gen sequencing amplicons (2025-04-01),

3. 11981966 - Methods for screening solid tumors for mutations (2024-05-14),

4. 11486007 - Methylated markers for colorectal cancer (2022-11-01),

5. 11085079 - Universal Sanger sequencing from next-gen sequencing amplicons (2021-08-10),

6. 11053542 - Compositions and methods for screening mutations in thyroid cancer (2021-07-06),

7. 10689710 - Methods for screening solid tumors for mutations (2020-06-23),

8. 10138519 - Universal sanger sequencing from next-gen sequencing amplicons (2018-11-27),

9. 8021837 - Detection of chromosomal abnormalities associated with breast cancer (2011-09-20),

10. 7537895 - Comparative genomic hybridization (2009-05-26),

11. 7534567 - Detection of nucleic acid sequence differences by comparative genomic hybridization (2009-05-19),

12. 7238484 - Comparative genomic hybridization (2007-07-03),

13. 7094534 - Detection of chromosoal abnormalities associated with breast cancer (2006-08-22),

14. 6335167 - Comparative genomic hybridization (CGH) (2002-01-01),

15. 6159685 - Comparative genomic hybridization (2000-12-11),

Title: Frederic Waldman: Innovating Cancer Treatment Methods

Introduction: Frederic Waldman, a talented inventor based in San Juan Capistrano, CA, has made significant contributions to the field of healthcare with his groundbreaking patent on screening solid tumors for mutations.

Latest Patents: Frederic Waldman's notable patent is on "Methods for screening solid tumors for mutations," revolutionizing the process of determining the efficacy of treatment for breast cancer, colorectal cancer, melanoma, and lung cancer. By detecting alterations in specific cancer-related genes, these methods guide personalized therapeutic decisions for patients.

Career Highlights: Waldman is associated with Quest Diagnostics Investments, Inc., a renowned company in the healthcare industry. His expertise and dedication have propelled him to the forefront of cancer research, striving to improve patient outcomes and advance medical technology.

Collaborations: Frederic has worked closely with his coworker, Kevin Qu, to further refine and implement his innovative screening methods. Together, they harness their collective knowledge and skills to develop cutting-edge solutions in the fight against cancer.

Conclusion: Frederic Waldman's pioneering work in cancer diagnostics stands as a testament to his passion for innovation and commitment to enhancing healthcare practices. His collaboration with industry leaders like Quest Diagnostics Investments, Inc., and coworker Kevin Qu, underscores his drive to make a meaningful impact on the lives of cancer patients worldwide.

Profile summary based on public USPTO records.